IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
CD20-positive Follicular Lymphoma, With Low Tumour Burden
Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
209 Active assets in the CD20-positive Follicular Lymphoma, With Low Tumour Burden cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
Romidepsin City of Hope Medical Center | Phase 2 | BBB |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
Recombinant Human Hyaluronidase National Cancer Institute (NCI) | Phase 3 | BBB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BBB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →